Colorectal cancer-review;Krabbamein í ristli og endaparmi

Laeknabladid

Volumn 100, Issue 2, 2014, Pages 75-83

  Haraldsdottir, S ^a   Einarsdottir, H M ^b   Smaradottir, A ^c   Gunnlaugsson, A ^d   Halfdanarson, Th R ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Oncology Dep   (Iceland)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Colon cancer; Colorectal cancer; Prognosis; Radiation therapy; Rectal cancer; Screening; Surgery; Therapy

Indexed keywords

AGE; COLORECTAL TUMOR; HUMAN; INCIDENCE; MULTIMODALITY CANCER THERAPY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

AGE FACTORS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896340510     PISSN: 00237213     EISSN: 16704959     Source Type: Journal    
DOI: 10.17992/lbl.2014.02.531     Document Type: Review

References (114)

1. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58: 130-60
2. Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer screening-optimizing current strategies and new directions. Nat Rev Clin Oncol 2013; 10: 130-42
3. Engholm G, Ferlay J, Christensen N, Johannesen TB, Klint A, Kotlum JE, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the NordicCountries, Version 5.3 (25.04.2013). Association of theNordic Cancer Registries. Danish Cancer Society. ancr. nu-október 2013
4. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-94
5. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 2009;18: 1695-8
6. Snaebjornsson P, Jonasson L, Jonsson T, Moller PH, Theodors A, Jonasson JG. Colon cancer in Iceland-a nationwide comparative study on various pathologyparameters with respect to right and left tumor location and patients age. Int J Cancer 2010; 127: 2645-53
7. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev 2012; 21: 411-6
8. Thorn M, Bergstrom R, Kressner U, Sparen P, Zack M, Ekbom A. Trends in colorectal cancer incidence in Sweden 1959-93 by gender, localization, time period, and birthcohort. Cancer Causes Control 1998; 9: 145-52
9. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National CancerInstitute. Bethesda, MD, seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012
10. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
11. Alexiusdottir KK, Moller PH, Snaebjornsson P, Jonasson L, Olafsdottir EJ, Bjornsson ES, et al. Association of symptoms of colon cancer patients with tumor location and TNM tumor stage. Scand J Gastroenterol. 2012; 47: 795-801
12. SEER Stat Fact Sheets: Colorectal Cancer (seer.cancer.gov/statfacts/html/ colorect.html). Vol. 2009
13. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-32
14. Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. NationalPolyp Study Workgroup. N Engl J Med 1996; 334: 82-7
15. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658-62
16. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.Gastroenterology 2010; 138: 746-74, 774 e741-744; quize712-743
17. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a metaanalysis. JAMA 2008; 300: 2765-78
18. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical Activity and Risks of Proximal and Distal Colon Cancers: A Systematic Review and Meta-analysis. J Natl Cancer Inst2012; 104: 1548-61
19. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomisedcontrolled trials. Lancet 2012; 379: 1591-601
20. Park Y, Leitzmann MF, Subar AF, Hollenbeck A, Schatzkin A. Dairy food, calcium, and risk of cancer in the NIHAARP Diet and Health Study. Arch Intern Med 2009; 169:391-401
21. Park Y, Hunter DJ, Spiegelman D, Bergkvist L, Berrino F, van den Brandt PA, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005; 294: 2849-57
22. Koushik A, Hunter DJ, Spiegelman D, Beeson WL, van den Brandt PA, Buring JE, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies.J Natl Cancer Inst 2007; 99: 1471-83
23. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 2006; 119: 2657-64
24. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001; 48: 812-5
25. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newlydiagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993; 328: 901-6
26. Theodórs Á, Sigurdsson F, Jónsson JS, Cariglia N, Ólafsson S, Stefánsson T. Skimun fyrir krabbameinum í ristli og endaparmi. Klínískar leidbeiningar. Landlæ knisembættid2002. landlaeknir.is/gaedi-og-eftirlit/heilbrigdisstarfsfolk/ klininskar-leidbeiningar/leidbeiningar/item15089/ Ristilkrabbamein- febrúar 2013
27. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369: 1095-105
28. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106-14
29. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706
30. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high riskgroups (update from 2002). Gut 2010; 59: 666-89
31. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3.2013. 2012
32. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93: 583-96
33. Otchy D, Hyman NH, Simmang C, Anthony T, Buie WD, Cataldo P, et al. Practice parameters for colon cancer. Dis Colon Rectum 2004; 47: 1269-84
34. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344: 707-11
35. Senagore AJ, Warmuth AJ, Delaney CP, Tekkis PP, Fazio VW. POSSUM, p-POSSUM, and Cr-POSSUM: implementation issues in a United States health care system for prediction of outcome for colon cancer resection. Dis Colon Rectum 2004; 47: 1435-41
36. Langevin JM, Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study. Am J Surg 1984; 147: 330-3
37. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-9
38. Fleshman J, Sargent DJ, Green E, Anvari M, Stryker SJ, Beart RW, Jr., et al. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg 2007; 246: 655-62; discussion662-54
39. Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, Haglind E, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol 2009; 10: 44-52
40. Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomisedtrial. Lancet Oncol 2005; 6: 477-84
41. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomized controlled trial. Lancet 2005; 365: 1718-26
42. Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 2007; 25: 3061-8
43. Luglio G, Nelson H. Laparoscopy for colon cancer: state of the art. Surg Oncol Clin N Am 2010; 19: 777-91
44. Turnbull RB, Jr., Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann Surg 1967; 166: 420-7
45. Rouffet F, Hay JM, Vacher B, Fingerhut A, Elhadad A, Flamant Y, et al. Curative resection for left colonic carcinoma: hemicolectomy vs. segmental colectomy. A prospective, controlled, multicenter trial. French Associationfor Surgical Research. Dis Colon Rectum 1994; 37: 651-9
46. Law CH, Wright FC, Rapanos T, Alzahrani M, Hanna SS, Khalifa M, et al. Impact of lymph node retrieval and pathological ultra-staging on the prognosis of stage IIcolon cancer. J Surg Oncol 2003; 84: 120-6
47. Whelan RL, Wong WD, Goldberg SM, Rothenberger DA. Synchronous bowel anastomoses. Dis Colon Rectum 1989; 32: 365-8
48. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatmentin stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-16
49. Benson AB, 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19
50. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516
51. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010; 375: 1030-47
52. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, et al. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-basedvalidation of numeracy and adjuvant! online. Cancer 2011; 117: 4155-65
53. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer:a systematic review and meta-analysis. JAMA 2011; 305: 2335-42
54. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N EnglJ Med 2004; 350: 2343-51
55. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-704
56. Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosedafter age 75 years. J Clin Oncol 2012; 30: 2624-34
57. Tournigand C, Andre T, Bo nnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatmentof Colon Cancer trial. J Clin Oncol 2012; 30: 3353-60
58. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin- based chemotherapy as adjuvant treatment for coloncancer (AVANT): a phase 3 randomised controlled trial.Lancet Oncol 2012; 13: 1225-33
59. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival amongpatients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383-93
60. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancerstudies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-70
61. Mant D, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial. J Clin Oncol 2013; 31 (suppl; abstr3500)
62. Desch CE, Benson AB, 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of ClinicalOncology practice guideline. J Clin Oncol 2005; 23: 8512-9
63. Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53: 1354-62
64. Minsky BD. Progress in the treatment of locally advanced clinically resectable rectal cancer. Clin Colorectal Cancer 2011; 10: 227-37
65. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40
66. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336: 980-7
67. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with t3 rectal cancer:trans-tasman radiation oncology group trial 01.04. J Clin Oncol 2012; 30: 3827-33
68. Guillem JG, Diaz-Gonzalez JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008; 26: 368-73
69. Guillem JG, Chessin DB, Shia J, Suriawinata A, Riedel E, Moore HG, et al. A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincterpreservation. Ann Surg 2007; 245: 88-93
70. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm.Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000; 356: 93-6
71. Qi Y, Stoddard D, Monson Jr. Indications and techniques of transanal endoscopic microsurgery (TEMS). J Gastrointest Surg 2011; 15: 1306-8
72. Brodsky JT, Richard GK, Cohen AM, Minsky BD. Variables correlated with the risk of lymph node metastasis in early rectal cancer. Cancer 1992; 69: 322-6
73. Garcia-Aguilar J, Mellgren A, Sirivongs P, Buie D, Madoff RD, Rothenberger DA. Local excision of rectal cancer without adjuvant therapy: a word of caution. Ann Surg 2000;231: 345-51
74. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-82
75. Heald RJ. The ,Holy Plane' of rectal surgery. J R Soc Med 1988; 81: 503-8
76. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silva e Sousa AH, Jr., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer followingchemoradiation therapy: long-term results. Ann Surg 2004; 240: 711-7; discussion 717-8
77. Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 2012; 256: 965-72
78. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 3: CD004078
79. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusionfluorouracil with radiation therapy after curative surgery.N Engl J Med 1994; 331: 502-7
80. Baron TH, Wong Kee Song LM, Repici A. Role of selfexpandable stents for patients with colon cancer (with videos). Gastrointest Endosc 2012; 75: 653-62
81. Faron M, Bourredjem A, Pignon JP, Bouche O, Douillard JY, Adenis A, et al. Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: Pooled analysis of individual patients'data from four randomized trials. J Clin Oncol 2012; 30 (suppl; abstr 3507)
82. Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database SystRev 2012; 8: CD008997
83. McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patientspresenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012; 30: 3223-38
84. Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. Cancer 2008; 112: 1879-91
85. Gray BN. Colorectal cancer: the natural history of disseminated disease-a review. Aust N Z J Surg 1980; 50: 643-6
86. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26: 5721-7
87. Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11: 155-66
88. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless ofwhether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23: 9441-2
89. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: arandomized GERCOR study. J Clin Oncol 2004; 22: 229-37
90. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer?The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727-33
91. de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, et al. Reintroduction of oxaliplatin is associated with improved survival in advancedcolorectal cancer. J Clin Oncol 2007; 25: 3224-9
92. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-5
93. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17
94. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14
95. Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 2011; 47: 1343-54
96. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan(FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-13
97. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9
98. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45
99. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis,with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12: 89
100. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy inmetastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9
101. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan ImprovesSurvival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. J Clin Oncol 2012; 30: 3499-506
102. Rinaldi F, George E, Adler AI. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol 2012; 13: 233-4
103. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled,phase 3 trial. Lancet 2013; 381: 303-12
104. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase IIItrials N9741 and N9841. J Clin Oncol 2012; 30: 263-7
105. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-32
106. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 2012; 13: e362-369
107. Sargent DJ, Kohne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data frompatients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 1948-55
108. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-80
109. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-22, discussion 722-4
110. Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag PM, Rougier P, et al. EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. J Clin Oncol 2012; 30 (suppl; abstr 3508)
111. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone forresectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-16
112. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J 2010; 16: 125-31
113. Vidarsdottir H, Moller PH, Gudbjartsson T. Skurdmedferd lungnameinvarpa-yfirlitsgrein um ábendingar og árangur medferdar. Læknabladid 2013; 99: 137-43
114. de Haas RJ, Adam R, Wicherts DA, Azoulay D, Bismuth H, Vibert E, et al. Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases.Br J Surg 2010; 97: 1279-89